- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02173756
Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults (MorphinOgel)
Chemotherapy kills tumor cells but can also damage healthy cells and cause significant digestive disorders such as ulcers of the mouth, called mucositis. Mucositis are transient but their intensity may require special measures. Mucositis are painful and morphine gel or intravenous morphine is used to relieve pain.
However, the pain of oral mucositis induced by chemotherapy is not completely relieved by morphine administered intravenously.
As part of the study, the investigators want to evaluate an oral gel containing a small amount of morphine so that it acts directly on the mucositis. The investigators believe that the direct action of morphine on mucositis may be more effective on pain.
Study Overview
Detailed Description
The objective of the study is to compare the analgesic efficacy of topical morphine gel versus placebo gel in the pediatric oncohaematology oral mucositis induced by chemotherapy in children treated with systemic opioids.
To confirm these results, we propose to conduct a randomized double-blinded study designed to compare the analgesic efficacy of morphine oral topical gel versus placebo gel in children over 5 years with mucositis induced by chemotherapy and treated with systemic opioids. This analgesic effect should reduce persistent pain to maintain oral feeding and thus delay the implementation of parenteral nutrition, and hence reduce the dose of systemic morphine and also reduce the adverse effects of opioids
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Patrick Lutz, MD
- Phone Number: 0388128091
- Email: patrick.lutz@chru-strasbourg.fr
Study Locations
-
-
Alsace
-
Strasbourg, Alsace, France, 67098
- Service d'oncohématologie pédiatrique, Hôpital de Hautepierre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children older than 5 years or adults over 18 and up to 25 years with a chemotherapy
- greater than or equal to grade 2 mucositis that has lasted for 24 hours and treated with systemic opioid
Exclusion Criteria:
- Patients in emergency ward -Patients having difficulties in understanding the study -
- Patients who have already been treated with oral morphine gel
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: oral morphine gel
1 mg / ml of Morphine hydrochloride, presented in a 5 mL sterile syringe (single dose).
Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
|
1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
Other Names:
|
Placebo Comparator: placebo gel
1 mg / ml of Placebo gel that is presented in a 5 mL sterile syringe (single dose).
Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
|
Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in pain of mucositis before and after meal
Time Frame: Daily assessment through out the mucositis
|
Pain is assessed before gel application and 30 minutes after application (i e 8 times per day and for the duration of the mucositis between 8 to 21 days).
The gel is administered 4 times daily 30 minutes before each meal.
Response to treatment is defined as a greater than or equal to 30% decrease in pain level between before and after application of the gel.
|
Daily assessment through out the mucositis
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the local tolerance and other topical treatment taken throughout the mucositis
Time Frame: daily, 8-21 days throughout the mucositis
|
Evaluation of the local tolerance ( taste, burns) with a questionnaire
|
daily, 8-21 days throughout the mucositis
|
Evaluation of the local tolerance and other topical treatment taken throughout the mucositis
Time Frame: daily, 8-21 days throughout the mucositis
|
Assessment of the quantity of morphine in mg/ day (reported in mg morphine), the nature and amount of all systemic analgesics
|
daily, 8-21 days throughout the mucositis
|
Evaluation of the local tolerance and other topical treatment taken throughout the mucositis
Time Frame: daily, 8-21 days throughout the mucositis
|
Daily grading of mucositis by the doctor
|
daily, 8-21 days throughout the mucositis
|
Evaluation of the local tolerance and other topical treatment taken throughout the mucositis
Time Frame: daily, 8-21 days throughout the mucositis
|
Daily evaluation of other topical treatments administered (mouthwashes: time frames when administered, doses, nature)
|
daily, 8-21 days throughout the mucositis
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5092
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on morphine gel
-
Institut CurieAssistance Publique - Hôpitaux de Paris; Hôpital Louis MourierTerminatedChronic Wounds | Local PainFrance
-
The Metis FoundationRecruitingBurns | Wound of SkinUnited States
-
Hospital General de Niños Pedro de ElizaldeWithdrawn
-
Banner HealthUnknown
-
Institute of Child HealthCompleted
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Glyciome, LLCBrigham and Women's Hospital; University of Puerto RicoCompletedSensory Perceptual Characteristics | User Acceptability of Gel Delivery SystemUnited States, Puerto Rico
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
Novan, Inc.CompletedAcne VulgarisDominican Republic, Honduras, Panama
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)